The European Commission has announced significant changes that may soon reshape MedTech regulation in Europe. The first step on this path is to gather proposals and views from manufacturers, clinicians, notified bodies, and patient organizations.
Author: Dzmitry Korsak
Dzmitry Korsak
Experienced journalist and editor with over 25 years in the field. His work focuses on medical technologies, social issues, and innovation. He values an evidence-based approach, thorough work with primary sources, and the ability to communicate complex topics in a clear and accessible way.
Theranostics in nuclear medicine is a modern, mainstream approach that unites cancer diagnosis and treatment into a single, integrated system. It not only enables precise identification of tumors and their metastases but also allows targeted radionuclide therapy. Today, these methods are increasingly being included in international treatment protocols and offer patients a real chance to extend their lives and improve quality of life.
When people talk about digital health, they usually mean Zoomers and Millennials. A Rock Health (2024) survey shows: 68% of Millennials and 60% of Zoomers used virtual healthcare over the past year. Against this backdrop, it’s easy to believe that the healthtech market is aimed only at the young.
About 52,500 U.S. Medicare beneficiaries use remote patient monitoring (RPM) services — primarily for hypertension, diabetes, and musculoskeletal conditions. In Medicare Advantage plans, remote monitoring uptake has surged 14-fold from 2019 to 2022.
Today, the scientific community is actively discussing an experimental mRNA-based cancer vaccine developed at the University of Florida. It’s important to emphasize: this is not a preventive vaccine like those used against COVID‑19.